Abstract
An important role for donor-specific antibodies (DSA) to mismatched human leukocyte antigens (HLA) in lung allograft rejection has been recognized since the late 1990s. Early studies identified the development of HLA antibodies as a risk factor for chronic rejection. Recently, antibody-mediated rejection (AMR) has been increasingly recognized as a form of lung allograft rejection, and the International Society for Heart and Lung Transplantation proposed a consensus definition. However, experience with AMR after lung transplantation remains limited, and outcomes are poor with many patients dying of AMR or developing progressive chronic rejection after the diagnosis.
| Original language | English |
|---|---|
| Title of host publication | Encyclopedia of Respiratory Medicine, Second Edition |
| Publisher | Elsevier |
| Pages | 735-740 |
| Number of pages | 6 |
| Volume | 5 |
| ISBN (Electronic) | 9780081027240 |
| ISBN (Print) | 9780081027233 |
| DOIs | |
| State | Published - Jan 1 2021 |
Keywords
- Antibody-mediated rejection
- Bronchiolitis obliterans syndrome
- Chronic lung allograft dysfunction
- Donor-specific antibodies
- Human leukocyte antigens
- Immunosuppression
- Lung transplantation
- Outcomes
- Restrictive allograft syndrome
- Survival